| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18726312eff9eb2bd2f380dd8189ec20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 |
| filingDate |
2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7a33ed522988f7f4ed32fd751c5780 |
| publicationDate |
2016-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3049088-A1 |
| titleOfInvention |
Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring |
| abstract |
A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2α) or a PGF 2α analog directly to the area of atrophic scarring. |
| priorityDate |
2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |